References
- Song F, Glenny AM, Altman DG. Indirect comparison in evaluating relative efficacy – illustrated by antimicrobial prophylaxis in colorectal surgery. Contr Clin Trials 2000;21:488–97
- Glenny AM, Altman DG, Song F, et al. Indirect comparison of competing interventions. Health Technology Assessment 2005, in press
- Rudy D, Cline K, Goldberg K, et al. A multicenter, phase III trial studying trospium chloride in patients with overactive bladder. Urology 2005, in press
- Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919–24
- Cardozo L, Robinson D, Diogendijk T, for the Solifenacin Study Group. Solifenacin statistically significantly increases continence rates in subjects with symptoms of the overactive bladder syndrome [Abstract 141]. International Continence Society Annual Conference, Paris, France, 2004
- Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind, placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303–10
- Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171:2311–5
- Abrams P, Foote J, Lheritier K. Urinary continence during darifenacin therapy for overactive bladder (OAB): pooled data from phase III trials [Abstract 229]. Euro Urol 2005;Suppl 4:60